secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVANOS MEDICAL, INC. (AVNS)
CIK:        0001606498
Form:       8-K
Filed at:   2026-07-14T23:18:06+00:00
Accession:  0001606498-26-000093
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avanos supplements proxy with additional M&A details amid stockholder lawsuits; merger on track
--------------------------------------------------------------------------------

- Two stockholder lawsuits filed June 29-30, 2026 in NY Supreme Court seeking to enjoin merger; demand letters also received alleging proxy deficiencies.
- Avanos voluntarily supplements proxy with additional background on AIP's contact with UBS, UBS conflict disclosure, and estimated UBS fee of not more than $5M.
- JP Morgan's public trading multiples analysis shows implied per share equity value range of $12.75-$23.50 vs. merger consideration of $25.00.
- JP Morgan's selected transactions analysis shows implied per share equity value range of $9.75-$21.75 vs. merger consideration of $25.00.
- Special meeting still set for July 22, 2026; board continues to unanimously recommend approval of merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1606498/000160649826000093/0001606498-26-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1606498/000160649826000093/avns-20260714.htm
  HTML page:      https://secwatch.observer/filing/0001606498-26-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer